Drug Profile
WS 7528
Latest Information Update: 23 Jun 1998
Price :
$50
*
At a glance
- Originator Fujisawa
- Class Anti-inflammatories; Antineoplastics
- Mechanism of Action Estrogen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 23 Jun 1998 Commercial data has been reviewed by Fujisawa
- 21 Apr 1998 Profile reviewed
- 21 Apr 1998 No-Development-Reported for Cancer in Japan (Unknown route)